{"nctId":"NCT00444457","briefTitle":"Study Evaluating 13-valent Pneumococcal Conjugate Vaccine In Healthy Infants","startDateStruct":{"date":"2007-05"},"conditions":["Vaccines, Pneumococcal"],"count":1712,"armGroups":[{"label":"1","type":"EXPERIMENTAL","interventionNames":["Biological: 13-valent Pneumococcal Conjugate Vaccine"]},{"label":"2","type":"EXPERIMENTAL","interventionNames":["Biological: 13-valent Pneumococcal Conjugate Vaccine"]},{"label":"3","type":"EXPERIMENTAL","interventionNames":["Biological: 13-valent Pneumococcal Conjugate Vaccine"]},{"label":"4","type":"ACTIVE_COMPARATOR","interventionNames":["Biological: 7vPnC"]}],"interventions":[{"name":"13-valent Pneumococcal Conjugate Vaccine","otherNames":[]},{"name":"7vPnC","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion criteria:\n\n* Healthy 2 month old infants\n* Available for the duration of the study and reachable by telephone\n* Able to complete two blood drawing procedures during the study\n\nExclusion criteria:\n\n* Previous vaccination, contraindication or history of allergic reaction to vaccines or vaccine components\n* Bleeding disorder, immune deficiency or significant chronic or congenital disease\n* Previous receipt of blood products or immune globulin","healthyVolunteers":true,"sex":"ALL","minimumAge":"42 Days","maximumAge":"98 Days","stdAges":["CHILD"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Geometric Mean Concentration (GMC) for Serotype-specific Pneumococcal Immunoglobulin G (IgG) Antibody in the Three 13vPnC Groups 1 Month After the Infant Series","description":"Antibody geometric mean concentration (GMC) as measured by micrograms per milliliter (mcg/mL) for 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A) are presented. GMC (13vPnC) and corresponding 2-sided 95% confidence intervals (CI) were evaluated. Geometric means (GMs) were calculated using all participants with available data for the specified blood draw.","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.33","spread":null},{"groupId":"OG001","value":"1.34","spread":null},{"groupId":"OG002","value":"1.75","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.89","spread":null},{"groupId":"OG001","value":"2.15","spread":null},{"groupId":"OG002","value":"2.54","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.05","spread":null},{"groupId":"OG001","value":"1.11","spread":null},{"groupId":"OG002","value":"1.11","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.97","spread":null},{"groupId":"OG001","value":"5.13","spread":null},{"groupId":"OG002","value":"5.18","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.30","spread":null},{"groupId":"OG001","value":"1.34","spread":null},{"groupId":"OG002","value":"1.48","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.85","spread":null},{"groupId":"OG001","value":"2.07","spread":null},{"groupId":"OG002","value":"2.59","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.24","spread":null},{"groupId":"OG001","value":"1.27","spread":null},{"groupId":"OG002","value":"1.03","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.62","spread":null},{"groupId":"OG001","value":"1.81","spread":null},{"groupId":"OG002","value":"1.91","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.52","spread":null},{"groupId":"OG001","value":"0.56","spread":null},{"groupId":"OG002","value":"0.61","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.35","spread":null},{"groupId":"OG001","value":"1.05","spread":null},{"groupId":"OG002","value":"1.35","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.40","spread":null},{"groupId":"OG001","value":"2.10","spread":null},{"groupId":"OG002","value":"2.12","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.54","spread":null},{"groupId":"OG001","value":"2.52","spread":null},{"groupId":"OG002","value":"2.67","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.85","spread":null},{"groupId":"OG001","value":"2.00","spread":null},{"groupId":"OG002","value":"1.88","spread":null}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants Achieving Predefined Antibody Level ≥0.1 International Units Per Milliliter (IU/mL) for Tetanus Toxoid in the Combined 13vPnC Group Relative to 7vPnC Group 1 Month After the Infant Series","description":"Percentage of participants achieving predefined antibody threshold ≥0.1 IU/ mL along with the corresponding 95% CI for concomitant antigen tetanus toxoid are presented. Exact 2-sided CI was based on the observed proportion of participants. Combined 13vPnC group includes participants randomized to pilot lot 1, pilot lot 2, or the manufacturing lot.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"98.4","spread":null},{"groupId":"OG001","value":"98.5","spread":null}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants Achieving Predefined Antibody Level ≥1:8 for Poliovirus in the Combined 13vPnC Group Relative to 7vPnC Group 1 Month After the Infant Series","description":"Percentage of participants achieving predefined antibody threshold ≥1:8 along with the corresponding 95% CI for concomitant antigen poliovirus type 1, type 2, and type 3 (Sabin strains 1, 2, 3) are presented. Exact 2-sided CI was based on the observed proportion of participants. Combined 13vPnC group includes participants randomized to pilot lot 1, pilot lot 2, or the manufacturing lot.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"100.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"98.9","spread":null},{"groupId":"OG001","value":"99.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"99.5","spread":null}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants Achieving Predefined Antibody Level ≥10.0 Milli-International Units Per Milliliter (mIU/mL) for Hepatitis B in the Combined 13vPnC Group Relative to 7vPnC Group 1 Month After the Infant Series","description":"Percentage of participants achieving predefined antibody threshold ≥10.0 mIU/ mL along with the corresponding 95% CI for concomitant antigen hepatitis B are presented. Exact 2-sided CI was based on the observed proportion of participants. Combined 13vPnC group includes participants randomized to pilot lot 1, pilot lot 2, or the manufacturing lot.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"100.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Achieving Serotype-specific Pneumococcal IgG Antibody Level ≥0.35 Mcg/mL in the Three 13vPnC Groups 1 Month After the Infant Series","description":"Percentage of participants achieving predefined antibody threshold ≥0.35mcg/mL along with the corresponding 95% CI for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) are presented. Exact 2-sided CI based on the observed proportion of participants.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"97.6","spread":null},{"groupId":"OG001","value":"95.5","spread":null},{"groupId":"OG002","value":"98.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"94.9","spread":null},{"groupId":"OG001","value":"89.5","spread":null},{"groupId":"OG002","value":"94.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"95.4","spread":null},{"groupId":"OG001","value":"95.5","spread":null},{"groupId":"OG002","value":"96.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"99.2","spread":null},{"groupId":"OG001","value":"99.0","spread":null},{"groupId":"OG002","value":"98.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"97.8","spread":null},{"groupId":"OG001","value":"95.8","spread":null},{"groupId":"OG002","value":"98.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"97.8","spread":null},{"groupId":"OG001","value":"97.5","spread":null},{"groupId":"OG002","value":"99.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"91.2","spread":null},{"groupId":"OG001","value":"88.1","spread":null},{"groupId":"OG002","value":"87.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"97.8","spread":null},{"groupId":"OG001","value":"97.0","spread":null},{"groupId":"OG002","value":"98.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"68.5","spread":null},{"groupId":"OG001","value":"72.4","spread":null},{"groupId":"OG002","value":"79.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"94.2","spread":null},{"groupId":"OG001","value":"90.3","spread":null},{"groupId":"OG002","value":"94.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"98.1","spread":null},{"groupId":"OG001","value":"95.5","spread":null},{"groupId":"OG002","value":"98.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"99.8","spread":null},{"groupId":"OG001","value":"99.0","spread":null},{"groupId":"OG002","value":"99.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"98.1","spread":null},{"groupId":"OG001","value":"99.0","spread":null},{"groupId":"OG002","value":"98.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Achieving Serotype-specific Pneumococcal IgG Antibody Level ≥0.35 Mcg/mL in the Three 13vPnC Groups 1 Month After the Toddler Dose","description":"Percentage of participants achieving predefined antibody threshold ≥0.35 mcg/mL along with the corresponding 95% CI for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) are presented. Exact 2-sided CI based on the observed proportion of participants.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"99.2","spread":null},{"groupId":"OG001","value":"99.1","spread":null},{"groupId":"OG002","value":"100.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"100.0","spread":null},{"groupId":"OG002","value":"100.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"99.7","spread":null},{"groupId":"OG001","value":"99.7","spread":null},{"groupId":"OG002","value":"99.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"99.7","spread":null},{"groupId":"OG002","value":"100.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"98.9","spread":null},{"groupId":"OG001","value":"98.5","spread":null},{"groupId":"OG002","value":"99.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"98.3","spread":null},{"groupId":"OG001","value":"98.8","spread":null},{"groupId":"OG002","value":"99.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"99.4","spread":null},{"groupId":"OG001","value":"99.1","spread":null},{"groupId":"OG002","value":"98.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"99.1","spread":null},{"groupId":"OG002","value":"99.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"83.6","spread":null},{"groupId":"OG001","value":"80.8","spread":null},{"groupId":"OG002","value":"88.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"99.7","spread":null},{"groupId":"OG001","value":"99.4","spread":null},{"groupId":"OG002","value":"99.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"100.0","spread":null},{"groupId":"OG002","value":"99.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"99.4","spread":null},{"groupId":"OG002","value":"99.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"100.0","spread":null},{"groupId":"OG002","value":"100.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Achieving Serotype-specific Pneumococcal IgG Antibody Level ≥1.00 Mcg/mL in the Combined 13vPnC Group 1 Month After the Infant Series","description":"Percentage of participants achieving predefined antibody threshold ≥1.00 mcg/mL along with the corresponding 95% CI for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) are presented. Exact 2-sided CI based on the observed proportion of participants.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"70.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"78.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"55.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"95.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"68.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"85.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"60.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"75.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"21.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"60.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"85.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"92.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"80.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Achieving Serotype-specific Pneumococcal IgG Antibody Level ≥1.00 Mcg/mL in the Three 13vPnC Groups 1 Month After the Toddler Dose","description":"Percentage of participants achieving predefined antibody threshold ≥1.00 mcg/mL along with the corresponding 95% CI for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) are presented. Exact 2-sided CI based on the observed proportion of participants.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"86.0","spread":null},{"groupId":"OG001","value":"87.4","spread":null},{"groupId":"OG002","value":"92.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"99.5","spread":null},{"groupId":"OG001","value":"99.1","spread":null},{"groupId":"OG002","value":"99.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"80.7","spread":null},{"groupId":"OG001","value":"84.5","spread":null},{"groupId":"OG002","value":"85.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"98.6","spread":null},{"groupId":"OG001","value":"98.8","spread":null},{"groupId":"OG002","value":"98.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"79.6","spread":null},{"groupId":"OG001","value":"85.0","spread":null},{"groupId":"OG002","value":"89.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"94.5","spread":null},{"groupId":"OG001","value":"95.3","spread":null},{"groupId":"OG002","value":"97.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"91.7","spread":null},{"groupId":"OG001","value":"91.2","spread":null},{"groupId":"OG002","value":"89.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"91.8","spread":null},{"groupId":"OG001","value":"91.0","spread":null},{"groupId":"OG002","value":"94.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"32.0","spread":null},{"groupId":"OG001","value":"30.3","spread":null},{"groupId":"OG002","value":"36.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"94.0","spread":null},{"groupId":"OG001","value":"91.0","spread":null},{"groupId":"OG002","value":"93.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"99.2","spread":null},{"groupId":"OG001","value":"98.2","spread":null},{"groupId":"OG002","value":"99.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"98.1","spread":null},{"groupId":"OG001","value":"96.2","spread":null},{"groupId":"OG002","value":"98.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"99.4","spread":null},{"groupId":"OG002","value":"99.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Geometric Mean Concentration (GMC) for Serotype-specific Pneumococcal Immunoglobulin G (IgG) Antibody in the Three 13vPnC Groups 1 Month After the Toddler Dose","description":"Antibody geometric mean concentration (GMC) as measured by mcg/mL for 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A) are presented. GMC (13vPnC) and corresponding 2-sided 95% confidence intervals (CI) were evaluated. Geometric means (GMs) were calculated using all participants with available data for the specified blood draw.","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.29","spread":null},{"groupId":"OG001","value":"2.25","spread":null},{"groupId":"OG002","value":"3.06","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11.14","spread":null},{"groupId":"OG001","value":"9.33","spread":null},{"groupId":"OG002","value":"9.92","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.91","spread":null},{"groupId":"OG001","value":"1.95","spread":null},{"groupId":"OG002","value":"1.99","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.61","spread":null},{"groupId":"OG001","value":"7.05","spread":null},{"groupId":"OG002","value":"6.91","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.95","spread":null},{"groupId":"OG001","value":"2.20","spread":null},{"groupId":"OG002","value":"2.48","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.51","spread":null},{"groupId":"OG001","value":"4.67","spread":null},{"groupId":"OG002","value":"6.51","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.35","spread":null},{"groupId":"OG001","value":"3.46","spread":null},{"groupId":"OG002","value":"3.10","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.75","spread":null},{"groupId":"OG001","value":"2.95","spread":null},{"groupId":"OG002","value":"3.01","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.75","spread":null},{"groupId":"OG001","value":"0.71","spread":null},{"groupId":"OG002","value":"0.80","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.11","spread":null},{"groupId":"OG001","value":"2.63","spread":null},{"groupId":"OG002","value":"2.80","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.52","spread":null},{"groupId":"OG001","value":"6.97","spread":null},{"groupId":"OG002","value":"6.83","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.35","spread":null},{"groupId":"OG001","value":"4.24","spread":null},{"groupId":"OG002","value":"4.58","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.41","spread":null},{"groupId":"OG001","value":"8.32","spread":null},{"groupId":"OG002","value":"8.60","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Percentage of Participants Reporting Local Reactions in the Three 13vPnC Groups and 7vPnC Group: Infant Series Dose 1 (2 Months of Age)","description":"Local reactions were reported using an electronic diary. Tenderness was scaled as Any (tenderness present); Significant (present and interfered with limb movement). Induration and erythema were scaled as Any (induration or erythema present); Mild (0.5 centimeters \\[cm\\] to 2.0 cm); Moderate (2.5 to 7.0 cm); Severe (\\> 7.0 cm). Participants may be represented in more than 1 category.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"62.4","spread":null},{"groupId":"OG001","value":"64.1","spread":null},{"groupId":"OG002","value":"62.5","spread":null},{"groupId":"OG003","value":"67.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9.2","spread":null},{"groupId":"OG001","value":"10.4","spread":null},{"groupId":"OG002","value":"10.4","spread":null},{"groupId":"OG003","value":"12.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"16.6","spread":null},{"groupId":"OG001","value":"19.6","spread":null},{"groupId":"OG002","value":"19.3","spread":null},{"groupId":"OG003","value":"18.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"14.7","spread":null},{"groupId":"OG001","value":"16.9","spread":null},{"groupId":"OG002","value":"15.5","spread":null},{"groupId":"OG003","value":"16.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.6","spread":null},{"groupId":"OG001","value":"5.8","spread":null},{"groupId":"OG002","value":"5.0","spread":null},{"groupId":"OG003","value":"3.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null},{"groupId":"OG001","value":"0.0","spread":null},{"groupId":"OG002","value":"0.0","spread":null},{"groupId":"OG003","value":"0.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"19.4","spread":null},{"groupId":"OG001","value":"25.0","spread":null},{"groupId":"OG002","value":"23.1","spread":null},{"groupId":"OG003","value":"22.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"18.1","spread":null},{"groupId":"OG001","value":"24.7","spread":null},{"groupId":"OG002","value":"21.2","spread":null},{"groupId":"OG003","value":"21.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.1","spread":null},{"groupId":"OG001","value":"0.6","spread":null},{"groupId":"OG002","value":"2.4","spread":null},{"groupId":"OG003","value":"1.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null},{"groupId":"OG001","value":"0.0","spread":null},{"groupId":"OG002","value":"0.0","spread":null},{"groupId":"OG003","value":"0.0","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Percentage of Participants Reporting Local Reactions in the Three 13vPnC Groups and 7vPnC Group: Infant Series Dose 2 (4 Months of Age)","description":"Local reactions were reported using an electronic diary. Tenderness was scaled as Any (tenderness present); Significant (present and interfered with limb movement). Induration and erythema were scaled as Any (induration or erythema present); Mild (0.5 cm to 2.0 cm); Moderate (2.5 to 7.0 cm); Severe (\\> 7.0 cm). Participants may be represented in more than 1 category.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"66.4","spread":null},{"groupId":"OG001","value":"67.3","spread":null},{"groupId":"OG002","value":"65.0","spread":null},{"groupId":"OG003","value":"64.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9.7","spread":null},{"groupId":"OG001","value":"7.4","spread":null},{"groupId":"OG002","value":"12.2","spread":null},{"groupId":"OG003","value":"11.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"24.4","spread":null},{"groupId":"OG001","value":"22.6","spread":null},{"groupId":"OG002","value":"28.7","spread":null},{"groupId":"OG003","value":"17.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"22.6","spread":null},{"groupId":"OG001","value":"22.0","spread":null},{"groupId":"OG002","value":"26.8","spread":null},{"groupId":"OG003","value":"17.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.1","spread":null},{"groupId":"OG001","value":"1.3","spread":null},{"groupId":"OG002","value":"4.7","spread":null},{"groupId":"OG003","value":"3.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null},{"groupId":"OG001","value":"0.0","spread":null},{"groupId":"OG002","value":"0.4","spread":null},{"groupId":"OG003","value":"0.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"30.1","spread":null},{"groupId":"OG001","value":"35.8","spread":null},{"groupId":"OG002","value":"34.5","spread":null},{"groupId":"OG003","value":"30.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"28.4","spread":null},{"groupId":"OG001","value":"34.6","spread":null},{"groupId":"OG002","value":"33.3","spread":null},{"groupId":"OG003","value":"28.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.4","spread":null},{"groupId":"OG001","value":"1.8","spread":null},{"groupId":"OG002","value":"3.2","spread":null},{"groupId":"OG003","value":"3.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null},{"groupId":"OG001","value":"0.0","spread":null},{"groupId":"OG002","value":"0.0","spread":null},{"groupId":"OG003","value":"0.0","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Percentage of Participants Reporting Local Reactions in the Three 13vPnC Groups and 7vPnC Group: Infant Series Dose 3 (6 Months of Age)","description":"Local reactions were reported using an electronic diary. Tenderness was scaled as Any (tenderness present); Significant (present and interfered with limb movement). Induration and erythema were scaled as Any (induration or erythema present); Mild (0.5 cm to 2.0 cm); Moderate (2.5 to 7.0 cm); Severe (\\> 7.0 cm). Participants may be represented in more than 1 category.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"62.5","spread":null},{"groupId":"OG001","value":"60.9","spread":null},{"groupId":"OG002","value":"55.0","spread":null},{"groupId":"OG003","value":"64.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.9","spread":null},{"groupId":"OG001","value":"7.5","spread":null},{"groupId":"OG002","value":"10.1","spread":null},{"groupId":"OG003","value":"11.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"27.0","spread":null},{"groupId":"OG001","value":"23.6","spread":null},{"groupId":"OG002","value":"28.6","spread":null},{"groupId":"OG003","value":"30.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"24.6","spread":null},{"groupId":"OG001","value":"22.5","spread":null},{"groupId":"OG002","value":"27.3","spread":null},{"groupId":"OG003","value":"29.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.1","spread":null},{"groupId":"OG001","value":"4.1","spread":null},{"groupId":"OG002","value":"3.9","spread":null},{"groupId":"OG003","value":"7.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null},{"groupId":"OG001","value":"0.0","spread":null},{"groupId":"OG002","value":"0.0","spread":null},{"groupId":"OG003","value":"0.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"39.6","spread":null},{"groupId":"OG001","value":"35.9","spread":null},{"groupId":"OG002","value":"37.6","spread":null},{"groupId":"OG003","value":"39.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"37.1","spread":null},{"groupId":"OG001","value":"33.8","spread":null},{"groupId":"OG002","value":"36.4","spread":null},{"groupId":"OG003","value":"38.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.3","spread":null},{"groupId":"OG001","value":"4.1","spread":null},{"groupId":"OG002","value":"5.6","spread":null},{"groupId":"OG003","value":"7.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null},{"groupId":"OG001","value":"0.0","spread":null},{"groupId":"OG002","value":"0.0","spread":null},{"groupId":"OG003","value":"0.0","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Percentage of Participants Reporting Local Reactions in the Combined 13vPnC Group and 7vPnC Group: Toddler Dose (12 Months of Age)","description":"Local reactions were reported using an electronic diary. Tenderness was scaled as Any (tenderness present); Significant (present and interfered with limb movement). Induration and erythema were scaled as Any (induration or erythema present); Mild (0.5 cm to 2.0 cm); Moderate (2.5 to 7.0 cm); Severe (\\> 7.0 cm). Participants may be represented in more than 1 category.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"57.3","spread":null},{"groupId":"OG001","value":"63.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.7","spread":null},{"groupId":"OG001","value":"4.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"31.5","spread":null},{"groupId":"OG001","value":"43.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"28.9","spread":null},{"groupId":"OG001","value":"41.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.5","spread":null},{"groupId":"OG001","value":"17.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null},{"groupId":"OG001","value":"0.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"42.6","spread":null},{"groupId":"OG001","value":"52.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"39.2","spread":null},{"groupId":"OG001","value":"50.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10.6","spread":null},{"groupId":"OG001","value":"21.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null},{"groupId":"OG001","value":"0.0","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Percentage of Participants Reporting Systemic Events in the Three 13vPnC Groups and 7vPnC Group: Infant Series Dose 1 (2 Months of Age)","description":"Systemic events (any fever ≥ 38 degrees Celsius \\[C\\], decreased appetite, irritability, increased sleep, decreased sleep, and hives \\[urticaria\\]) were reported using an electronic diary. Participants may be represented in more than 1 category.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"24.6","spread":null},{"groupId":"OG001","value":"23.4","spread":null},{"groupId":"OG002","value":"24.6","spread":null},{"groupId":"OG003","value":"26.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.6","spread":null},{"groupId":"OG001","value":"0.3","spread":null},{"groupId":"OG002","value":"0.9","spread":null},{"groupId":"OG003","value":"1.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null},{"groupId":"OG001","value":"0.0","spread":null},{"groupId":"OG002","value":"0.3","spread":null},{"groupId":"OG003","value":"0.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"50.6","spread":null},{"groupId":"OG001","value":"46.0","spread":null},{"groupId":"OG002","value":"50.0","spread":null},{"groupId":"OG003","value":"49.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"85.7","spread":null},{"groupId":"OG001","value":"84.3","spread":null},{"groupId":"OG002","value":"89.1","spread":null},{"groupId":"OG003","value":"87.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"71.5","spread":null},{"groupId":"OG001","value":"72.7","spread":null},{"groupId":"OG002","value":"69.4","spread":null},{"groupId":"OG003","value":"72.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"44.1","spread":null},{"groupId":"OG001","value":"46.9","spread":null},{"groupId":"OG002","value":"42.2","spread":null},{"groupId":"OG003","value":"46.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.6","spread":null},{"groupId":"OG001","value":"0.9","spread":null},{"groupId":"OG002","value":"0.6","spread":null},{"groupId":"OG003","value":"0.0","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Percentage of Participants Reporting Systemic Events in the Three 13vPnC Groups and 7vPnC Group: Infant Series Dose 2 (4 Months of Age)","description":"Systemic events (any fever ≥ 38 degrees C, decreased appetite, irritability, increased sleep, decreased sleep, and hives \\[urticaria\\]) were reported using an electronic diary. Participants may be represented in more than 1 category.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"33.4","spread":null},{"groupId":"OG001","value":"36.4","spread":null},{"groupId":"OG002","value":"35.5","spread":null},{"groupId":"OG003","value":"28.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.4","spread":null},{"groupId":"OG001","value":"3.2","spread":null},{"groupId":"OG002","value":"3.6","spread":null},{"groupId":"OG003","value":"0.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.4","spread":null},{"groupId":"OG001","value":"0.0","spread":null},{"groupId":"OG002","value":"0.0","spread":null},{"groupId":"OG003","value":"0.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"48.4","spread":null},{"groupId":"OG001","value":"49.1","spread":null},{"groupId":"OG002","value":"48.0","spread":null},{"groupId":"OG003","value":"49.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"86.5","spread":null},{"groupId":"OG001","value":"86.5","spread":null},{"groupId":"OG002","value":"84.6","spread":null},{"groupId":"OG003","value":"81.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"64.8","spread":null},{"groupId":"OG001","value":"68.2","spread":null},{"groupId":"OG002","value":"67.3","spread":null},{"groupId":"OG003","value":"63.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"49.1","spread":null},{"groupId":"OG001","value":"48.8","spread":null},{"groupId":"OG002","value":"44.6","spread":null},{"groupId":"OG003","value":"48.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.4","spread":null},{"groupId":"OG001","value":"2.2","spread":null},{"groupId":"OG002","value":"1.6","spread":null},{"groupId":"OG003","value":"0.8","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Percentage of Participants Reporting Systemic Events in the Three 13vPnC Groups and 7vPnC Group: Infant Series Dose 3 (6 Months of Age)","description":"Systemic events (any fever ≥ 38 degrees C, decreased appetite, irritability, increased sleep, decreased sleep, and hives \\[urticaria\\]) were reported using an electronic diary. Participants may be represented in more than 1 category.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"26.3","spread":null},{"groupId":"OG001","value":"27.6","spread":null},{"groupId":"OG002","value":"31.7","spread":null},{"groupId":"OG003","value":"32.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.5","spread":null},{"groupId":"OG001","value":"3.7","spread":null},{"groupId":"OG002","value":"5.6","spread":null},{"groupId":"OG003","value":"6.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null},{"groupId":"OG001","value":"0.5","spread":null},{"groupId":"OG002","value":"0.0","spread":null},{"groupId":"OG003","value":"0.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"45.8","spread":null},{"groupId":"OG001","value":"48.0","spread":null},{"groupId":"OG002","value":"50.7","spread":null},{"groupId":"OG003","value":"50.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"79.5","spread":null},{"groupId":"OG001","value":"80.5","spread":null},{"groupId":"OG002","value":"82.7","spread":null},{"groupId":"OG003","value":"84.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"55.4","spread":null},{"groupId":"OG001","value":"58.8","spread":null},{"groupId":"OG002","value":"59.8","spread":null},{"groupId":"OG003","value":"51.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"42.6","spread":null},{"groupId":"OG001","value":"50.4","spread":null},{"groupId":"OG002","value":"48.4","spread":null},{"groupId":"OG003","value":"56.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.7","spread":null},{"groupId":"OG001","value":"0.9","spread":null},{"groupId":"OG002","value":"1.7","spread":null},{"groupId":"OG003","value":"1.8","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Percentage of Participants Reporting Systemic Events in the Combined 13vPnC Group and 7vPnC Group: Toddler Dose (12 Months of Age)","description":"Systemic events (any fever ≥ 38 degrees C, decreased appetite, irritability, increased sleep, decreased sleep, and hives \\[urticaria\\]) were reported using an electronic diary. Participants may be represented in more than 1 category.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"28.8","spread":null},{"groupId":"OG001","value":"29.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.4","spread":null},{"groupId":"OG001","value":"5.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.0","spread":null},{"groupId":"OG001","value":"0.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"51.9","spread":null},{"groupId":"OG001","value":"50.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"81.8","spread":null},{"groupId":"OG001","value":"80.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"47.8","spread":null},{"groupId":"OG001","value":"47.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"46.9","spread":null},{"groupId":"OG001","value":"42.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.1","spread":null},{"groupId":"OG001","value":"5.2","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":13,"n":486},"commonTop":["Irritability","Tenderness (any)","Increased sleep","Decreased appetite","Irritability"]}}}